Silence Therapeutics PLC Sponsored ADR (SLN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The powe ...

Full Year 2024 Results February 27, 2025 Forward-Looking Statements The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation in certain jurisdictions may be restricted by law, and persons into whose possession this presentation comes should inform themselves about, and observe, any such restric ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-39487 Silence Therapeutics plc (Exact name of registrant as specified in its charter) Tel: +44 20 3457 6900 (State ...

Exhibit 99.1 Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update The Company's cash guidance is now extended into 2027 Company to host conference call and webcast today at 8 a.m. EST / 1 p.m. GMT 27 February 2025 LONDON, Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the full year ended December 31, 2024, and provided a ...

Financial Data and Key Metrics Changes - For the year ended December 31, 2024, the company recorded revenues of $43.3 million, an increase from $31.6 million in 2023, representing a growth of $11.7 million largely due to collaboration arrangements for siRNA platform development [20][21] - The company's net operating loss for 2024 was approximately $63.3 million, a slight decrease from $64.4 million in 2023, attributed to increased revenue offset by rising R&D costs [26] - The net loss for 2024 was approximately $45.3 million compared to $54.2 million in 2023, reflecting improved financial performance [27] Business Line Data and Key Metrics Changes - The Phase 2 study of zerlasiran showed positive results with Lp(a) reductions exceeding 90%, supporting its competitive profile for further development [5][6] - Divesiran's Phase 1 study eliminated the need for phlebotomy in all well-controlled patients, indicating strong efficacy and safety [8][44] - The company plans to prioritize investment in programs targeting rare conditions, with divesiran for polycythemia vera (PV) remaining a top priority [10][29] Market Data and Key Metrics Changes - The company anticipates full enrollment in the SANRECO Phase 2 study for divesiran by the end of 2024, indicating strong market interest and potential for future growth [15][30] - The collaboration with AstraZeneca continues to advance, with expectations for additional milestones [20][21] Company Strategy and Development Direction - The company will only initiate the Phase 3 outcomes study for zerlasiran once a partner is secured, extending its cash runway into 2027 [12][28] - The focus remains on developing innovative siRNA therapies for rare conditions, leveraging the company's proprietary pipeline [10][29] - The company is evaluating multiple undisclosed programs from its GOLD platform for potential development or partnership [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of zerlasiran and divesiran, highlighting the unique market opportunities for both products [12][60] - The company is actively engaged in partnership discussions for zerlasiran, with a focus on securing the right partner for development and commercialization [61] Other Important Information - Silence has transitioned to a U.S. domestic issuer effective January 1, 2025, requiring compliance with U.S. GAAP and SEC reporting [19] - The company recorded approximately $4.5 million in other income, primarily from U.S. treasury bill accretion, compared to $1.8 million in 2023 [27] Q&A Session Summary Question: Can you provide some color on partnership discussions for zerlasiran? - Management refrained from commenting specifically on ongoing partnership discussions but noted increased funding for Lp(a) studies from companies like Novartis [59][61] Question: How ready is the company for the Phase 3 trial of zerlasiran? - The company is wrapping up Phase 3 readiness activities and is prepared to make adjustments with a partner if needed [67] Question: What are the goals for divesiran regarding differentiation? - The company aims to be the first siRNA to market for PV, focusing on infrequent dosing and symptomatic improvement as key differentiators [75][76] Question: What are the biggest hurdles for partnering zerlasiran? - Hurdles vary by party, often revolving around business strategy and recognition of the large market opportunity [79][80] Question: What is the status of the candidates developed for Hansoh? - The company is interested in the programs developed in partnership with Hansoh and plans to evaluate them for potential internal development or partnership [84][86]

Shares of Silence Therapeutics (SLN) plunged 36.8% on Tuesday despite reporting positive end-of-treatment data from a mid-stage study of lead candidate, zerlasiran, to treat atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) or Lp(a), a key genetic risk factor for cardiovascular disease. The stock price drop is likely due to investors’ skepticism regarding the effectiveness of the candidate compared to other treatments being developed for the same indication.The results from th ...

On Monday, Silence Therapeutics plc SLN presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L).These data were presented at the American Heart Association (AHA) Scientific Sessions.Results showed that zerlasiran (300 mg every 16 weeks, 300 mg every 24 weeks or 450 mg every 24 weeks) produced greater than 80% mean time-averaged placebo-adjusted reductions from baseline in ...

Exhibit 99.1 Condensed consolidated income statement (unaudited) | --- | --- | --- | --- | --- | |---------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|------------------------------------------------------------|--------------------------------------------------------| | £000s (except per share information) | Three months ended \nSeptember 30, 2024 \n£000s | Three months ended \nS ...

Pathompong Thongsan/iStock via Getty Images Silence Therapeutics plc (NASDAQ:SLN) develops RNA interference ("RNAI") therapies that silence genes associated with various diseases. SLN employs its proprietary mRNAi GOLD platform to produce short interfering RNAs (siRNAs) that degrade disease-related mRNA. It focuses especially on genes expressed in the liver, which is an ideal target due to its essential role in metabolism and regulating proteins, fats, and carbohydrates. Currently, SLNCF's main drug candida ...

andresr/E+ via Getty Images The last time I wrote about Silence Therapeutics plc (NASDAQ:SLN) it was in a Seeking Alpha article entitled "Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results." With this article, I noted that the company had already released positive results using one of its small interfering RNA [siRNA] candidates, known as zerlasiran. This is for the treatment of patients with elevated levels of Lp[a] at high risk of atherosclerotic cardiovascular disease [ASCVD]. ...